Ascites levels of haptoglobin in patients with ovarian cancer

S. A. Elg, L. F. Carson, J. M. Fowler, L. B. Twiggs, M. M. Moradi, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. Haptoglobin is an acute-phase reactant protein involved in immune regulation. It has been isolated from malignant ovarian ascites and has been shown to be capable of mediating nonspecific immune suppression in vitro in humans and in vivo in experimental animals. The range of concentrations under which such a nonspecific suppression is observed lies well within concentrations of haptoglobin observed in vivo. This immune suppression could adversely affect patient outcome. Methods. Based on this information, ascites haptoglobin levels of 21 consecutive patients with ovarian cancer who underwent initial surgical debulking were determined. After the patients received chemotherapy, they were divided into those having a positive and those have a negative second-look operation. Results. Seventeen patients with positive pathology at second look had an initial mean ascites haptoglobin level of 99 ± 49 mg/dl. The mean haptoglobin level in the four patients with negative findings was 67 ± 42 mg/dl. The difference in these mean haptoglobin levels is not statistically significant (P > 0.05). Conclusion. Although the number of patients in this study is small, the wide range of values documented in both groups make it doubtful that an initial absolute ascites haptoglobin level will prove clinically prognostic of eventual disease status at the time of second look laparotomy.

Original languageEnglish
Pages (from-to)3938-3941
Number of pages4
JournalCancer
Volume71
Issue number12
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Haptoglobins
Ascites
Ovarian Neoplasms
Acute-Phase Proteins
Laparotomy
Pathology
Drug Therapy

Keywords

  • ascites
  • haptoglobin
  • ovarian cancer
  • prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elg, S. A., Carson, L. F., Fowler, J. M., Twiggs, L. B., Moradi, M. M., & Ramakrishnan, S. (1993). Ascites levels of haptoglobin in patients with ovarian cancer. Cancer, 71(12), 3938-3941.

Ascites levels of haptoglobin in patients with ovarian cancer. / Elg, S. A.; Carson, L. F.; Fowler, J. M.; Twiggs, L. B.; Moradi, M. M.; Ramakrishnan, Sundaram.

In: Cancer, Vol. 71, No. 12, 01.01.1993, p. 3938-3941.

Research output: Contribution to journalArticle

Elg, SA, Carson, LF, Fowler, JM, Twiggs, LB, Moradi, MM & Ramakrishnan, S 1993, 'Ascites levels of haptoglobin in patients with ovarian cancer', Cancer, vol. 71, no. 12, pp. 3938-3941.
Elg SA, Carson LF, Fowler JM, Twiggs LB, Moradi MM, Ramakrishnan S. Ascites levels of haptoglobin in patients with ovarian cancer. Cancer. 1993 Jan 1;71(12):3938-3941.
Elg, S. A. ; Carson, L. F. ; Fowler, J. M. ; Twiggs, L. B. ; Moradi, M. M. ; Ramakrishnan, Sundaram. / Ascites levels of haptoglobin in patients with ovarian cancer. In: Cancer. 1993 ; Vol. 71, No. 12. pp. 3938-3941.
@article{7b0896012862407793c3f075ca86aee2,
title = "Ascites levels of haptoglobin in patients with ovarian cancer",
abstract = "Background. Haptoglobin is an acute-phase reactant protein involved in immune regulation. It has been isolated from malignant ovarian ascites and has been shown to be capable of mediating nonspecific immune suppression in vitro in humans and in vivo in experimental animals. The range of concentrations under which such a nonspecific suppression is observed lies well within concentrations of haptoglobin observed in vivo. This immune suppression could adversely affect patient outcome. Methods. Based on this information, ascites haptoglobin levels of 21 consecutive patients with ovarian cancer who underwent initial surgical debulking were determined. After the patients received chemotherapy, they were divided into those having a positive and those have a negative second-look operation. Results. Seventeen patients with positive pathology at second look had an initial mean ascites haptoglobin level of 99 ± 49 mg/dl. The mean haptoglobin level in the four patients with negative findings was 67 ± 42 mg/dl. The difference in these mean haptoglobin levels is not statistically significant (P > 0.05). Conclusion. Although the number of patients in this study is small, the wide range of values documented in both groups make it doubtful that an initial absolute ascites haptoglobin level will prove clinically prognostic of eventual disease status at the time of second look laparotomy.",
keywords = "ascites, haptoglobin, ovarian cancer, prognosis",
author = "Elg, {S. A.} and Carson, {L. F.} and Fowler, {J. M.} and Twiggs, {L. B.} and Moradi, {M. M.} and Sundaram Ramakrishnan",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "71",
pages = "3938--3941",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Ascites levels of haptoglobin in patients with ovarian cancer

AU - Elg, S. A.

AU - Carson, L. F.

AU - Fowler, J. M.

AU - Twiggs, L. B.

AU - Moradi, M. M.

AU - Ramakrishnan, Sundaram

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background. Haptoglobin is an acute-phase reactant protein involved in immune regulation. It has been isolated from malignant ovarian ascites and has been shown to be capable of mediating nonspecific immune suppression in vitro in humans and in vivo in experimental animals. The range of concentrations under which such a nonspecific suppression is observed lies well within concentrations of haptoglobin observed in vivo. This immune suppression could adversely affect patient outcome. Methods. Based on this information, ascites haptoglobin levels of 21 consecutive patients with ovarian cancer who underwent initial surgical debulking were determined. After the patients received chemotherapy, they were divided into those having a positive and those have a negative second-look operation. Results. Seventeen patients with positive pathology at second look had an initial mean ascites haptoglobin level of 99 ± 49 mg/dl. The mean haptoglobin level in the four patients with negative findings was 67 ± 42 mg/dl. The difference in these mean haptoglobin levels is not statistically significant (P > 0.05). Conclusion. Although the number of patients in this study is small, the wide range of values documented in both groups make it doubtful that an initial absolute ascites haptoglobin level will prove clinically prognostic of eventual disease status at the time of second look laparotomy.

AB - Background. Haptoglobin is an acute-phase reactant protein involved in immune regulation. It has been isolated from malignant ovarian ascites and has been shown to be capable of mediating nonspecific immune suppression in vitro in humans and in vivo in experimental animals. The range of concentrations under which such a nonspecific suppression is observed lies well within concentrations of haptoglobin observed in vivo. This immune suppression could adversely affect patient outcome. Methods. Based on this information, ascites haptoglobin levels of 21 consecutive patients with ovarian cancer who underwent initial surgical debulking were determined. After the patients received chemotherapy, they were divided into those having a positive and those have a negative second-look operation. Results. Seventeen patients with positive pathology at second look had an initial mean ascites haptoglobin level of 99 ± 49 mg/dl. The mean haptoglobin level in the four patients with negative findings was 67 ± 42 mg/dl. The difference in these mean haptoglobin levels is not statistically significant (P > 0.05). Conclusion. Although the number of patients in this study is small, the wide range of values documented in both groups make it doubtful that an initial absolute ascites haptoglobin level will prove clinically prognostic of eventual disease status at the time of second look laparotomy.

KW - ascites

KW - haptoglobin

KW - ovarian cancer

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=0027279058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027279058&partnerID=8YFLogxK

M3 - Article

C2 - 8389656

AN - SCOPUS:0027279058

VL - 71

SP - 3938

EP - 3941

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -